Whalesbook
UTI AMC Reports Q3 FY26 Financial Performance
UTI Asset Management Company (AMC) announced its financial results for the third quarter and nine months ended December 31, 2025. The company's consolidated Profit After Tax (PAT) for Q3 FY26 stood at ₹121 crore, representing a 20% decrease year-on-year. However, on a normalized basis, excluding exceptional items, PAT increased by 43% year-on-year to ₹216 crore [1, 6]. Consolidated revenue from operations saw a significant increase of 24% year-on-year, reaching ₹517 crore [1, 9]. On a standalone basis, core income grew by 5% year-on-year to ₹322 crore [3].
The quarter saw mixed fund flows, with net outflows of ₹220 crore in equity and hybrid segments. However, substantial inflows into Exchange Traded Funds (ETFs) and index funds contributed to total net inflows of ₹5,900 crore for the quarter. For the nine-month period of FY26, overall net inflows remained solid at ₹21,500 crore [1].
Asset Under Management and Operational Growth
UTI AMC's Quarterly Average Assets Under Management (QAAUM) expanded by 12% year-on-year to ₹3.9 lakh crore as of December 31, 2025 [1, 4]. The Systematic Investment Plan (SIP) asset under management demonstrated strong momentum, growing by 16.64% year-on-year to ₹44,752 crore [1, 3]. Despite this growth, the company continued to navigate market share challenges across its equity and hybrid portfolios [2, 4]. UTI AMC has been actively leveraging digital initiatives, with a high percentage of online sales and digital transaction processing, enhancing investor accessibility and experience [1, 3].
Market Reaction and Analyst Outlook
On January 22, 2026, UTI AMC's stock experienced upward momentum, rising over 3% and outperforming the broader market, as analysts responded positively to the results and an upgrade [4, 15]. This positive sentiment followed a notable correction of approximately 23% in the stock over the preceding three months, which analysts at Centrum Broking deemed excessive [4, 15].
Centrum Broking upgraded its rating on UTI AMC to 'Buy' from 'Neutral', citing attractive valuation metrics. The firm has set a revised target price of ₹1,278, based on valuing the stock at 18 times its FY28 estimated Earnings Per Share (EPS), representing an approximate 8% discount to its long-term average [4]. The stock was trading around ₹1,030-₹1,070 on January 22, 2026 [10, 11, 21].
Peer Comparison and Valuation Context
UTI AMC's current trading P/E ratio, estimated to be between 18.6 and 24.65 (TTM/recent), appears competitive when compared to larger peers like HDFC AMC (P/E 37.62) and ICICI Prudential AMC (P/E 47.53) [2, 7, 10, 11]. This relative valuation, coupled with the company's strategic focus on digital growth and a resilient SIP book, underpins the bullish outlook from some analysts [1, 3, 4]. However, persistent market share losses and the overall challenging fund flow environment, with significant outflows from financial services noted by some reports, remain key monitorables [2, 24].
Regulatory Filings
UTI Asset Management Company made relevant disclosures on January 21, 2026, including the release of its Q3 & 9M FY26 results and an investor presentation, filed under Regulation 30 (LODR) [2].